An observational study in Gastritis, Gastric Dysplasia and Gastric Ulcer, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Gastritis with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Gastritis · China.
Among the 31 studies in Gastritis with a site in China, this one is one of 7 that started in 2025, is one of 9 observational ones, and was the 28th registered.
136 studies on the registry are indexed under Gastritis; 24 are open to participants now.
Browse Gastritis studies →7 of the 31 studies in Gastritis with a site in China are open now. Recruiting first, the newest first:
Yongquan Shi · Sites in China
Ages 18–75
Yongquan Shi · Sites in China
Ages 18–70
RenJi Hospital · Sites in China
Ages 18–65
Jianning Yao · Sites in China
Changhai Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 45 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 206 across 38 observational studies indexed under Gastritis.
Median enrollment 520 across the 22 interventional studies, 200 across the 9 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.
Nanfang Hospital, Southern Medical University has 2 studies filed under Gastritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Gastritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations.
The main question it aims to answer is:
Can MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers?
Participants will:
Epidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.
Gastric diseases-including atrophic gastritis, gastric polyps, peptic ulcers, submucosal lesions, gastric cancer, and precancerous conditions-have become a major global public health challenge. In China, the prevalence of gastric ulcers is as high as 17.2%, significantly higher than that in Western countries (4.1%) [1]. Gastric cancer also ranks among the top globally in both incidence and mortality, with approximately 400,000 new cases and over 300,000 deaths each year [2-3]. Notably, around 80% of patients are diagnosed at an advanced stage, and the 5-year survival rate is less than 30% [4]. Studies have shown that early gastric cancer, if detected and treated promptly, can achieve a 5-year survival rate of over 90% [5]. Moreover, if benign conditions such as atrophic gastritis and peptic ulcers are not treated in time, they may progress into precancerous lesions or even malignancies [6]. Therefore, early screening and accurate diagnosis are key to reducing the disease burden of gastric disorders.
Although esophagogastroduodenoscopy (EGD) is considered the gold standard for gastric disease screening [7-8], its invasive nature, associated patient discomfort, and reliance on skilled endoscopists and specialized equipment limit its accessibility. In China, the scarcity of endoscopic resources in primary care settings, combined with low patient compliance, further restricts screening coverage and increases the risk of missed diagnoses [9-10].
In recent years, capsule endoscopy has emerged as a valuable complementary tool for gastrointestinal disease screening due to its non-invasive and user-friendly nature [6,7]. Among its modalities, magnetically controlled capsule gastroscopy (MCCG) provides comprehensive gastric visualization, with reported sensitivity and specificity of 90% and 92%, respectively, for common gastric lesions. However, its reliance on expensive magnetic navigation systems and trained operators limits its widespread adoption in community-based screening programs [8].
To address these limitations, a novel mobile-controlled capsule gastroscopy (MCG) system being more accessible and not requiring costly external magnetic control was developed. It consists only of a disposable capsule and a wireless portable receiver. Participants can complete the examination independently in community health centers or at home by following video instructions via a smartphone app and adjusting their body positions to guide the capsule. An AI algorithm ensures complete gastric coverage in real time. The video can be viewed directly on the smartphone and transmitted to the cloud for remote diagnosis. The MCG system is non-invasive, user-friendly, and compatible with remote diagnosis, making it well suited for gastric disease screening in community health centers. Compared with MCCG, MCG enables fully autonomous operation without magnetic navigation, substantially reducing technical complexity and healthcare costs. However, its diagnostic accuracy and real-world feasibility in community-based populations have yet to be validated through prospective studies.
In 2025, the Guangzhou Municipal Health Commission issued the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality'. Organized by the Commission and led by Southern Medical University Nanfang Hospital, with participation from Guangzhou First People's Hospital, The Second Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine, and others, the program will conduct screening and surveillance of 10,000 elderly and high-risk individuals in community health centers across Guangzhou.
This prospective cohort study will collect epidemiological data, examination results, follow-up outcomes, and other relevant information from the screening program. The primary endpoint is the detection rate of gastric pathologies, including common conditions (such as atrophic gastritis, gastric ulcers, and submucosal tumors), gastric cancer, and precancerous lesions. The operational feasibility, safety, and acceptability of the MCG system in primary care settings will also be assessed. Findings are expected to provide scientific evidence to support the optimization of gastric disease prevention and control strategies at the municipal level.
1. Baseline Period
2. Diagnostic \& Therapeutic Procedures
3. Follow-up prognostic data
3.1 Short-term follow-up will be conducted on Days 1, 3, and 14 following MCG.
3.2 Long-term follow-up will be conducted annually for a duration of five years through telephone interviews and/or routine monitoring at community health centers.
10,000 participants enrolled in the existing public welfare screening program: Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.Provision of written ; 2.Participants of the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality', the following are the criteria for inclusion in this public welfare programme:
Or high-risk cohort: Individuals aged ≥45 years who meet at least one of the following risk criteria:
Exclusion Criteria:
(1)Known allergy to medical polymer materials; (2)Psychiatric disorders that interfere with procedural cooperation; (3)Pregnancy or lactation; (4)Severe systemic comorbidities (e.g., cardiovascular, respiratory, neurological diseases) affecting examination tolerance; (5)Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or gastrointestinal diverticulosis; (6)Known or suspected gastrointestinal malformations, obstructions, strictures, or fistulas; (7) dysphagia; (8)Acute abdominal symptoms (e.g., pain, vomiting, suspected bowel obstruction, or severe constipation); (9)History of major gastrointestinal surgery (e.g., esophagogastrostomy, gastrojejunostomy); (10)Physical debilitation precludes postural changes or concurrent severe illness; (11)Medically ineligible for abdominal procedures or refusal to undergo them; (12)Deemed unsuitable for MCG by the investigator; (13)Refusal to provide ; (14)Any other condition judged by the investigator to make the individual unsuitable for study participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The enrolment group includes all subjects who will undergo MCG examination in the 'Gastric pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality'.
Other: Collect epidemiological, diagnostic, and follow-up data after MCG examination.
MCG System: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
Detection Rate of Gastric Diseases Using Mobile Capsule Gastroscopy
This measure assesses the proportion of participants in whom MCG identifies common gastric diseases, gastric cancer, or precancerous lesions.
Time frame: At end of data collection phase (within 6 months of study launch)
Safety of MCG
This outcome tracks the incidence and types of adverse events related to the MCG procedure, including capsule retention, discomfort, or complications requiring medical intervention.
Time frame: Within 14days after MCG procedure
Quality of MCG Examination
The coverage rate of gastric anatomical regions, the device failure rate, image quality, and mucosal visibility will be evaluated for all MCG examinations. Coverage for each anatomical region and overall gastric coverage will be calculated as: Coverage rate = Number of Regions Adequately Visualized / Total Number of Anatomical Regions The calculation formula for the incidence of device failure is as follows: Device failure rate = Number of Cases with Device Failure / Number of Cases. A three-level grading scale (excellent / good / poor) will be used to objectively assess the following imaging quality indicators: clarity, field of view, image stability, structural and detail resolution, stereoscopic perception, overall image impression, intragastric cleanliness, gastric lumen distension, and mucosal visualization.
Time frame: At end of data collection phase (within 6 months of study launch)
Procedural Compliance and Completion Rate
This outcome evaluates the proportion of participants who successfully complete the MCG exam without technical failure or early termination.
Time frame: Immediately after MCG procedure
Patient Satisfaction
Participant-reported satisfaction with the MCG procedure, assessed via structured survey covering aspects such as comfort and convenience.
Time frame: Immediately after MCG procedure
Cost-Effectiveness of MCG Screening
Evaluates the cost per case of gastric pathologies detected using MCG versus conventional methods, using health economic metrics such as cost-effectiveness ratio and incremental cost-effectiveness ratio (ICER).
Time frame: At end of data collection phase (within 6 months of study launch)
Diagnostic Agreement Between MCG and EGD (Kappa Value)
Measures the consistency of diagnosis between MCG and the gold-standard EGD in participants with suspicious MCG findings. The Kappa statistic will be calculated to quantify diagnostic agreement.
Time frame: Within 30 days after MCG for participants referred for confirmatory EGD
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →